First Tracks Biotherapeutics, Inc.
This prospectus supplement supplements information contained in the prospectus dated October 26, 2026 (the “Prospectus”), relating to the sale by the selli...
Lycia Therapeutics, Inc.
While Xolair has validated IgE inhibition in food allergy, first-generation IgE blockers remain constrained by challenges that may limit treatment accessib...
ADARx Pharmaceuticals, Inc.
The biopharmaceutical industry is characterized by rapidly advancing and changing technologies, intense competition and a strong emphasis on intellectual p...
Electra Therapeutics, Inc.
The biopharmaceutical industry is characterized by rapidly evolving science and technology, intense competition, and a strong emphasis on intellectual prop...
Latigo Biotherapeutics, Inc.
Today’s treatment paradigm for musculoskeletal pain consists of over-the-counter analgesics for mild to moderate symptoms, while moderate to severe pain is...
Parabilis Medicines, Inc.
The pharmaceutical industry is characterized by rapid technological evolution and intense competition. We face and will continue to face competition from p...
Hemab Therapeutics Holdings, Inc.
The biotechnology and pharmaceutical industries are characterized by rapidly advancing innovative technologies under intense competition with an emphasis o...
Avalyn Pharma Inc.
While there is no cure for pulmonary fibrosis, there are three FDA-approved therapies to treat pulmonary fibrosis: pirfenidone, or ESBRIET®, marketed by Le...